Skip to main content
NCBI home page
Sarcoma logoLink to Sarcoma
. 2003 Mar;7(1):13–17. doi: 10.1080/1357714031000114192

A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours

T Meyer 1, A Mctiernan 1, J Whelan 1,✉
PMCID: PMC2395514  PMID: 18521364

Abstract

Purpose. The prognosis for patients with Ewing's tumours who have metastases at presentation or who are refractory to standard chemotherapy regimens remains poor. There is therefore a need to evaluate the role of new agents. This report describes the initial results of a prospective phase II trial of docetaxel in patients with progressive or refractory Ewing's tumours.

Patients and methods. Fourteen patients with Ewing's tumours who had all relapsed or progressed after treatment with multi-drug cytotoxic therapy were treated with docetaxel 100 mg/m2 infused over 1 h, three weekly for a maximum of six cycles. Nine patients received granulocyte colony-stimulating factor with all cycles.

Results. A partial response was observed in one patient and stable disease in two. The remaining patients progressed on treatment. The major toxicity was myelosuppression and infection with 36% patients experiencing grade 3 or 4 neutropenia and/or infection.

Conclusion. Docetaxel appears to have some activity in Ewing's tumours even in heavily pre-treated patients. Further evaluation of its efficacy at an earlier stage of the disease is warranted.

Full Text

The Full Text of this article is available as a PDF (64.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacci G., Ferrari S., Bertoni F., Donati D., Bacchini P., Longhi A., Brach Del Prever A., Forni C., Rimondini S. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli. J Clin Oncol. 2000 Feb;18(4):885–892. doi: 10.1200/JCO.2000.18.4.885. [DOI] [PubMed] [Google Scholar]
  2. Blaney S. M., Needle M. N., Gillespie A., Sato J. K., Reaman G. H., Berg S. L., Adamson P. C., Krailo M. D., Bleyer W. A., Poplack D. G. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb;4(2):357–360. [PubMed] [Google Scholar]
  3. Blaney S. M., Seibel N. L., O'Brien M., Reaman G. H., Berg S. L., Adamson P. C., Poplack D. G., Krailo M. D., Mosher R., Balis F. M. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr;15(4):1538–1543. doi: 10.1200/JCO.1997.15.4.1538. [DOI] [PubMed] [Google Scholar]
  4. Burdach S., Jürgens H., Peters C., Nürnberger W., Mauz-Körholz C., Körholz D., Paulussen M., Pape H., Dilloo D., Koscielniak E. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol. 1993 Aug;11(8):1482–1488. doi: 10.1200/JCO.1993.11.8.1482. [DOI] [PubMed] [Google Scholar]
  5. Burgert E. O., Jr, Nesbit M. E., Garnsey L. A., Gehan E. A., Herrmann J., Vietti T. J., Cangir A., Tefft M., Evans R., Thomas P. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990 Sep;8(9):1514–1524. doi: 10.1200/JCO.1990.8.9.1514. [DOI] [PubMed] [Google Scholar]
  6. Cangir A., Vietti T. J., Gehan E. A., Burgert E. O., Jr, Thomas P., Tefft M., Nesbit M. E., Kissane J., Pritchard D. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer. 1990 Sep 1;66(5):887–893. doi: 10.1002/1097-0142(19900901)66:5<887::aid-cncr2820660513>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  7. Chan S., Friedrichs K., Noel D., Pintér T., Van Belle S., Vorobiof D., Duarte R., Gil Gil M., Bodrogi I., Murray E. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999 Aug;17(8):2341–2354. doi: 10.1200/JCO.1999.17.8.2341. [DOI] [PubMed] [Google Scholar]
  8. Craft A., Cotterill S., Malcolm A., Spooner D., Grimer R., Souhami R., Imeson J., Lewis I. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol. 1998 Nov;16(11):3628–3633. doi: 10.1200/JCO.1998.16.11.3628. [DOI] [PubMed] [Google Scholar]
  9. Delattre O., Zucman J., Melot T., Garau X. S., Zucker J. M., Lenoir G. M., Ambros P. F., Sheer D., Turc-Carel C., Triche T. J. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994 Aug 4;331(5):294–299. doi: 10.1056/NEJM199408043310503. [DOI] [PubMed] [Google Scholar]
  10. Edmonson J. H., Ebbert L. P., Nascimento A. G., Jung S. H., McGaw H., Gerstner J. B. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol. 1996 Dec;19(6):574–576. doi: 10.1097/00000421-199612000-00008. [DOI] [PubMed] [Google Scholar]
  11. Ferraresi V., Milella M., Vaccaro A., D'Ottavio A. M., Papaldo P., Nisticò C., Thorel M. F., Marsella A., Carpino A., Giannarelli D. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol. 2000 Apr;23(2):132–139. doi: 10.1097/00000421-200004000-00006. [DOI] [PubMed] [Google Scholar]
  12. Gore M. E., Levy V., Rustin G., Perren T., Calvert A. H., Earl H., Thompson J. M. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer. 1995 Oct;72(4):1016–1019. doi: 10.1038/bjc.1995.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nabholtz J. M., North S., Smylie M., Mackey J., Au H. J., Au R., Morrish D., Salter E., Tonkin K. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol. 2000 Apr;27(2 Suppl 3):11–18. [PubMed] [Google Scholar]
  14. Nabholtz J. M., Senn H. J., Bezwoda W. R., Melnychuk D., Deschênes L., Douma J., Vandenberg T. A., Rapoport B., Rosso R., Trillet-Lenoir V. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999 May;17(5):1413–1424. doi: 10.1200/JCO.1999.17.5.1413. [DOI] [PubMed] [Google Scholar]
  15. Patricio M. B., Vilhena M., Neves M., Raposo S., Catita J., De Sousa V., Martins A. G. Ewing's sarcoma in children: twenty-five years of experience at the Instituto Portugês de Oncologia de Francisco Gentil (I.P.O.F.G.). J Surg Oncol. 1991 May;47(1):37–40. doi: 10.1002/jso.2930470109. [DOI] [PubMed] [Google Scholar]
  16. Paulussen M., Ahrens S., Burdach S., Craft A., Dockhorn-Dworniczak B., Dunst J., Fröhlich B., Winkelmann W., Zoubek A., Jürgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998 Mar;9(3):275–281. doi: 10.1023/a:1008208511815. [DOI] [PubMed] [Google Scholar]
  17. Paulussen M., Ahrens S., Craft A. W., Dunst J., Fröhlich B., Jabar S., Rübe C., Winkelmann W., Wissing S., Zoubek A. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol. 1998 Sep;16(9):3044–3052. doi: 10.1200/JCO.1998.16.9.3044. [DOI] [PubMed] [Google Scholar]
  18. Price C. H., Jeffree G. M. Incidence of bone sarcoma in SW England, 1946-74, in relation to age, sex, tumour site and histology. Br J Cancer. 1977 Oct;36(4):511–522. doi: 10.1038/bjc.1977.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ringel I., Horwitz S. B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991 Feb 20;83(4):288–291. doi: 10.1093/jnci/83.4.288. [DOI] [PubMed] [Google Scholar]
  20. Salminen E., Bergman M., Huhtala S., Ekholm E. Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol. 1999 Apr;17(4):1127–1127. doi: 10.1200/JCO.1999.17.4.1127. [DOI] [PubMed] [Google Scholar]
  21. Sparano J. A., O'Neill A., Schaefer P. L., Falkson C. I., Wood W. C. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol. 2000 Jun;18(12):2369–2377. doi: 10.1200/JCO.2000.18.12.2369. [DOI] [PubMed] [Google Scholar]
  22. Thigpen J. T., Blessing J. A., Ball H., Hummel S. J., Barrett R. J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994 Sep;12(9):1748–1753. doi: 10.1200/JCO.1994.12.9.1748. [DOI] [PubMed] [Google Scholar]
  23. Verweij J., Catimel G., Sulkes A., Sternberg C., Wolff I., Aamdal S., van Hoesel Q. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 1995;31A Suppl 4:S21–S24. doi: 10.1016/0959-8049(95)00362-m. [DOI] [PubMed] [Google Scholar]
  24. Verweij J., Lee S. M., Ruka W., Buesa J., Coleman R., van Hoessel R., Seynaeve C., di Paola E. D., van Glabbeke M., Tonelli D. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 2000 May;18(10):2081–2086. doi: 10.1200/JCO.2000.18.10.2081. [DOI] [PubMed] [Google Scholar]
  25. Wexler L. H., DeLaney T. F., Tsokos M., Avila N., Steinberg S. M., Weaver-McClure L., Jacobson J., Jarosinski P., Hijazi Y. M., Balis F. M. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996 Aug 15;78(4):901–911. doi: 10.1002/(SICI)1097-0142(19960815)78:4<901::AID-CNCR30>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  26. van Hoesel Q. G., Verweij J., Catimel G., Clavel M., Kerbrat P., van Oosterom A. T., Kerger J., Tursz T., van Glabbeke M., van Pottelsberghe C. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1994 Jul;5(6):539–542. doi: 10.1093/oxfordjournals.annonc.a058909. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES